Physician profile
Jun C Kim
NPI 1831686757
$1,117.07
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2021: $528 · 2022: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $237.96 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $172.78 | 2021 | |
| Neurocrine Biosciences, INC. | $132.77 | 2021 | |
| Amarin Pharma, INC. | $124.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $119.35 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.96 | 2021 | |
| Novo Nordisk INC | $110.93 | 2019 | |
| Ucb, INC. | $85.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.34 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.